Staging and prognostication of multiple myeloma

Rafael Fonseca, Jorge Monge, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a heterogeneous disease that, over the past 15 years, has seen an increased understanding of its biology and of novel therapeutic options. Distinctive subtypes of the disease have been described, each with different outcomes and clinic-pathological features. Even though a detailed classification of MM into at least seven or eight major subtypes is possible, a more practical clinical approach can classify the disease into high-risk and non-high-risk MM. Such classification has permitted a more personalized approach to the management of the disease. Additionally, risk stratification should be included in outcome discussions with patients, as survival differs significantly by high-risk status. Nowadays, test for risk stratification are widely available and can be routinely used in the clinic. A greater understanding of the genetic abnormalities underlying the biology of MM will allow for the development of novel targeted therapies and better prognostic markers of the disease.

Original languageEnglish (US)
Pages (from-to)21-31
Number of pages11
JournalExpert Review of Hematology
Volume7
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

Multiple Myeloma
Disease Management
Survival
Therapeutics

Keywords

  • cytogenetics
  • gene expression profiling
  • genetics
  • induction
  • maintenance
  • multiple myeloma
  • prognosis
  • risk stratification
  • stem cell transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Staging and prognostication of multiple myeloma. / Fonseca, Rafael; Monge, Jorge; Dimopoulos, Meletios A.

In: Expert Review of Hematology, Vol. 7, No. 1, 02.2014, p. 21-31.

Research output: Contribution to journalArticle

Fonseca, Rafael ; Monge, Jorge ; Dimopoulos, Meletios A. / Staging and prognostication of multiple myeloma. In: Expert Review of Hematology. 2014 ; Vol. 7, No. 1. pp. 21-31.
@article{7e85e2efac514fefa37866b8cd5069c0,
title = "Staging and prognostication of multiple myeloma",
abstract = "Multiple myeloma (MM) is a heterogeneous disease that, over the past 15 years, has seen an increased understanding of its biology and of novel therapeutic options. Distinctive subtypes of the disease have been described, each with different outcomes and clinic-pathological features. Even though a detailed classification of MM into at least seven or eight major subtypes is possible, a more practical clinical approach can classify the disease into high-risk and non-high-risk MM. Such classification has permitted a more personalized approach to the management of the disease. Additionally, risk stratification should be included in outcome discussions with patients, as survival differs significantly by high-risk status. Nowadays, test for risk stratification are widely available and can be routinely used in the clinic. A greater understanding of the genetic abnormalities underlying the biology of MM will allow for the development of novel targeted therapies and better prognostic markers of the disease.",
keywords = "cytogenetics, gene expression profiling, genetics, induction, maintenance, multiple myeloma, prognosis, risk stratification, stem cell transplant",
author = "Rafael Fonseca and Jorge Monge and Dimopoulos, {Meletios A.}",
year = "2014",
month = "2",
doi = "10.1586/17474086.2014.882224",
language = "English (US)",
volume = "7",
pages = "21--31",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Staging and prognostication of multiple myeloma

AU - Fonseca, Rafael

AU - Monge, Jorge

AU - Dimopoulos, Meletios A.

PY - 2014/2

Y1 - 2014/2

N2 - Multiple myeloma (MM) is a heterogeneous disease that, over the past 15 years, has seen an increased understanding of its biology and of novel therapeutic options. Distinctive subtypes of the disease have been described, each with different outcomes and clinic-pathological features. Even though a detailed classification of MM into at least seven or eight major subtypes is possible, a more practical clinical approach can classify the disease into high-risk and non-high-risk MM. Such classification has permitted a more personalized approach to the management of the disease. Additionally, risk stratification should be included in outcome discussions with patients, as survival differs significantly by high-risk status. Nowadays, test for risk stratification are widely available and can be routinely used in the clinic. A greater understanding of the genetic abnormalities underlying the biology of MM will allow for the development of novel targeted therapies and better prognostic markers of the disease.

AB - Multiple myeloma (MM) is a heterogeneous disease that, over the past 15 years, has seen an increased understanding of its biology and of novel therapeutic options. Distinctive subtypes of the disease have been described, each with different outcomes and clinic-pathological features. Even though a detailed classification of MM into at least seven or eight major subtypes is possible, a more practical clinical approach can classify the disease into high-risk and non-high-risk MM. Such classification has permitted a more personalized approach to the management of the disease. Additionally, risk stratification should be included in outcome discussions with patients, as survival differs significantly by high-risk status. Nowadays, test for risk stratification are widely available and can be routinely used in the clinic. A greater understanding of the genetic abnormalities underlying the biology of MM will allow for the development of novel targeted therapies and better prognostic markers of the disease.

KW - cytogenetics

KW - gene expression profiling

KW - genetics

KW - induction

KW - maintenance

KW - multiple myeloma

KW - prognosis

KW - risk stratification

KW - stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84893287305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893287305&partnerID=8YFLogxK

U2 - 10.1586/17474086.2014.882224

DO - 10.1586/17474086.2014.882224

M3 - Article

C2 - 24483346

AN - SCOPUS:84893287305

VL - 7

SP - 21

EP - 31

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 1

ER -